Clinical Trials Search
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*0401 Positive Subjects with Advanced Cancers
The purpose of this study is to determine if the experimental product, KITE-718 is safe and effective in treating advanced cancer.
The primary objectives of Phase 1A are to evaluate the safety of KITE-718 and to determine a recommended Phase 1B dose. The primary objective of Phase 1B is to evaluate the efficacy of KITE-718, as measured by objective response rate (ORR). Secondary objectives include assessing the safety of KITE-718 and additional efficacy endpoints.
Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2 (); KITE-718 (); MESNA (); Proleukin (Interleukin-2); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)